W. R. Grace artificial liver
This article was originally published in The Gray Sheet
Executive Summary
W. R. Grace and Cedars-Sinai Medical Center of Los Angeles begin clinical study of a bioartificial liver system following FDA approval of an investigational new drug application for the system. The bioartificial liver, developed jointly by Grace and Cedars under an agreement announced in November ("The Gray Sheet" Nov. 22, 1993, In Brief), consists of "a hollow-fiber membrane cartridge filled with a matrix of pig liver cells" and is intended to act as a short-term bridge to transplant for patients with acute and chronic liver failure. The first phase of the trial will involve 12-20 patients and will take place at Cedars, with Phase II trials expected to begin in mid-1995
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.